v3.25.2
License Agreements - CAR-T Products License (Details) - License And Development Agreement With TDT
$ in Millions
1 Months Ended 12 Months Ended
Jun. 30, 2018
USD ($)
Milestone
Dec. 31, 2024
USD ($)
item
Dec. 31, 2018
USD ($)
CAR-T products and CAR-T Diagnostics      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Upfront payment of license agreement fees $ 5.0   $ 5.0
Annual maintenance fees $ 0.5 $ 0.5  
Unpaid annual maintenance fees, short term debt interest rate (%) 1.50% 1.50%  
Number of developmental and regulatory milestone payments for first product development 4 4  
Maximum aggregate milestone commitment fund for first product development $ 15.0 $ 15.0  
Number of developmental and regulatory milestone payments for each additional product development 4 4  
Maximum milestone commitment fund for each additional product development $ 7.5 $ 7.5  
CAR-T products and CAR-T Diagnostics | Net sales of period from first commercial sale until patent expires | Minimum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percentage of royalty fees (%) 10.00% 10.00%  
CAR-T products and CAR-T Diagnostics | Net sales of period from first commercial sale until patent expires | Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percentage of royalty fees (%) 15.00% 15.00%  
CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of years from first commercial sale of products (in years) 10 years 10 years  
CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products | Minimum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percentage of royalty fees (%) 5.00% 5.00%  
CAR-T products and CAR-T Diagnostics | 10 years from first commercial sale of products | Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percentage of royalty fees (%) 9.00% 9.00%  
Phase II and Phase III clinical trials of CAR-T Product | Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amount of fund obligated to advance for each phase $ 20.0 $ 20.0